Literature DB >> 28363437

Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy.

Hiroki Ishihara1, Tsunenori Kondo2, Kazuhiko Yoshida1, Kenji Omae1, Toshio Takagi1, Junpei Iizuka1, Kazunari Tanabe1.   

Abstract

BACKGROUND: The role of systemic inflammatory markers, including C-reactive protein (CRP), the neutrophil/lymphocyte ratio (NLR), and the platelet/lymphocyte ratio (PLR), in predicting survival for patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy (mTT) after first-line tyrosine kinase inhibitor failure remains unclear. Thus, we investigated the relationship between systemic inflammation and survival in such patients. PATIENTS AND METHODS: Sixty-three patients were evaluated. Progression-free survival (PFS) and overall survival (OS) after second-line mTT initiation were evaluated according to the inflammatory marker levels. In addition, the prognostic factors for survival were examined.
RESULTS: The receiver operating characteristic curves for CRP, NLR, and PLR had areas under the curve of 0.779, 0.619, and 0.655, respectively; no significant differences were noted. The corresponding cutoff values were 0.48, 2.53, and 183. Patients with higher CRP (n = 40), NLR (n = 32), and PLR (n = 22) levels had significantly lower PFS and OS than those with lower CRP, NLR, and PLR levels. Multivariate analyses showed that CRP was the sole independent predictor for PFS and OS.
CONCLUSION: Systemic inflammation is associated with survival after second-line mTT. In particular, CRP was a strong independent predictive biomarker of prognosis.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; C-reactive protein; Neutrophil/lymphocyte ratio; Platelet/lymphocyte ratio; mRCC

Mesh:

Substances:

Year:  2017        PMID: 28363437     DOI: 10.1016/j.clgc.2017.01.018

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  6 in total

1.  Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.

Authors:  Mehmet Asim Bilen; Giselle Marie Almeida Dutcher; Yuan Liu; Deepak Ravindranathan; Haydn T Kissick; Bradley C Carthon; Omer Kucuk; Wayne B Harris; Viraj A Master
Journal:  Clin Genitourin Cancer       Date:  2018-01-04       Impact factor: 2.872

2.  Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma.

Authors:  Hiroki Ishihara; Hidekazu Tachibana; Toshio Takagi; Tsunenori Kondo; Hironori Fukuda; Kazuhiko Yoshida; Junpei Iizuka; Hirohito Kobayashi; Masayoshi Okumi; Hideki Ishida; Kazunari Tanabe
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

3.  Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma.

Authors:  Hiroki Ishihara; Toshio Takagi; Tsunenori Kondo; Hironori Fukuda; Kazuhiko Yoshida; Junpei Iizuka; Kazunari Tanabe
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493

4.  Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.

Authors:  Kimiharu Takamatsu; Ryuichi Mizuno; Nobuyuki Tanaka; Toshikazu Takeda; Shinya Morita; Kazuhiro Matsumoto; Takeo Kosaka; Toshiaki Shinojima; Eiji Kikuchi; Hiroshi Asanuma; Masafumi Oyama; Shuji Mikami; Mototsugu Oya
Journal:  Int J Clin Oncol       Date:  2019-05-07       Impact factor: 3.402

5.  The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Xuemin Wang; Shiqiang Su; Yuanshan Guo
Journal:  Oncotarget       Date:  2017-09-20

6.  The platelet-to-lymphocyte ratio as a significant prognostic factor to predict survival outcomes in patients with synchronous metastatic renal cell carcinoma.

Authors:  Hyeong Dong Yuk; Minyong Kang; Eu Chang Hwang; Jae Young Park; Chang Wook Jeong; Cheryn Song; Seong Il Seo; Seok Soo Byun; Cheol Kwak; Sung Hoo Hong; Jinsoo Chung; Hakmin Lee
Journal:  Investig Clin Urol       Date:  2020-07-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.